Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2022 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
April 08, 2022 13:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...
April 04, 2022 08:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Present at April Investor Conferences

BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...
April 01, 2022 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
March 17, 2022 06:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22 Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b trial anticipated during...
March 08, 2022 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
March 03, 2022 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Present at March Investor Conferences

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
March 01, 2022 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
February 02, 2022 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
January 19, 2022 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...